Multiple sclerosis and related disorders
November 1, 2025
Yang Yang, Xinyi Duan, Jing Wang et al.
1 citation
Ofatumumab, a fully humanized anti-CD20 monoclonal antibody, is the only highly effective disease modifying therapy (DMT) approved for the treatment of relapsing multiple sclerosis (RMS) in China up to data. Real-world data are necessary to investigate the factors for switching from oral DMTs and to assess the effectiveness and safety of ofatumumab in the Chinese MS population. We conducted a...
Multiple sclerosis and related disorders
July 1, 2025
Darina Slezáková, Louise Mária Adamová, Peter Marček et al.
3 citations
Most of the patients with multiple sclerosis (MS) suffer from cognitive impairment, fatigue and/or mood disturbances. These symptoms are usually resistant to both disease-modifying and symptomatic treatment. Since there is a trend to a holistic approach to MS patients, we aimed to confirm the effect of combined cold exposure, controlled breathing and mindfulness - Wim Hof Method (WHM) - on...
Multiple sclerosis and related disorders
December 1, 2024
Tarunya Arun, Kate Petheram, Emma Tallantyre et al.
Therapeutics of neuroinflammatory disorders including multiple sclerosis is one of the fastest growing areas in neurology. However, pressures on higher specialty training in neurology together with an expanding curriculum have led to challenges in adequately preparing trainees for a subspecialist career. In this study we set out to understand current perceptions and barriers to training in...
Multiple sclerosis and related disorders
October 2023
Francesco Motolese, Domenica Stelitano, Jacopo Lanzone et al.
Multiple Sclerosis (MS) is a chronic disease with a high prevalence of neuropsychiatric symptoms. Mindfulness is a practice that encourages individuals to cultivate a present-focused, acceptance-based approach for managing psychological distress. Its positive effect on MS has been demonstrated, but learning such technique is expensive and time-consuming. In this study, we investigated the...
Multiple sclerosis and related disorders
November 2022
Dena Sadeghi-Bahmani, Leila Esmaeili, Faezeh Mokhtari et al.
Compared to the general population, individuals with multiple sclerosis (MS) report higher levels of insomnia, depression, fatigue, and paresthesia, and lower levels of emotional competencies (understanding emotions in self and others). Available treatments are limited, and novel approaches to reducing symptoms and enhancing emotional competencies in MS are needed. Two potentially beneficial...
Multiple sclerosis and related disorders
June 2022
Nupur Nag, Xirun Yang, George Jelinek et al.
Multiple sclerosis is a demyelinating autoimmune disease, presenting with heterogenous symptoms that impact daily living. Undertaking stress-reducing activities may reduce symptoms including depression and fatigue, and enhance mastery, the sense of control of one's life. We assessed cross-sectional associations of undertaking stress-reducing activities or meditation on depression, fatigue, and...
Multiple sclerosis and related disorders
February 1, 2022
E. Duraney, B. Schirda, J. Nicholas et al.
OBJECTIVES Emotion dysregulation plays a role in the development and maintenance of psychopathology. Given the higher rates of mood disturbances in people with multiple sclerosis (PwMS), there is a need to explore the relationships between metrics of emotion dysregulation and potential protective traits. Mindfulness, a multi-faceted trait characteristic reflecting present moment awareness, is...
Multiple sclerosis and related disorders
October 1, 2021
Jeffrey Landrigan, Kitti Bessenyei, Damian Leitner et al.
BACKGROUND Multiple sclerosis (MS) is a chronic demyelinating disease which leads to sensory, motor, autonomic, and cognitive symptoms. Cannabis is a common way for persons with MS (pwMS) to seek symptomatic therapy. Given the capacity for both cannabis and MS to cause cognitive impairment, it is important to determine whether there is any negative impact when the two co-occur. The objective of...